Sagimet Biosciences (NASDAQ: SGMT) shares moved higher after the company’s China partner, Ascletis Pharma, reported positive topline results from a long-term Phase 3 safety study…
Sagimet Biosciences (NASDAQ: SGMT) shares moved higher after the company’s China partner, Ascletis Pharma, reported positive topline results from a long-term Phase 3 safety study…